Metaplanet — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
ParcelBioparcelbio.comin𝕏Feb 2026
ParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
David Weinberg(Founder)inChris Carlson(Founder)in
BoardMorgan Cheatham(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.